EN SV HOME THERAPEUTIC AREAS SPECIALTY CARE PORTFOLIO Specialty Care portfolio Within the Specialty Care portfolio, we provide products for the treatment of genetic and metabolic diseases as well as a number of specialist indications. An example of a genetic metabolic disease is hereditary tyrosinaemia type 1 (HT-1). HT-1 is a condition where the body is unable to break down tyrosine, one of protein's essential building blocks. When the body cannot break down tyrosine, high levels build up in the blood and form a toxic substance known as succinylacetone. This means that if tyrosinaemia isn't treated, it may cause liver and kidney damage, neurological issues, and shorter life expectancy. The most severe form of tyrosinaemia, HT-1 is thought to affect one person in every 100,000 to 120,000 worldwide. Affecting males and females equally, it must be inherited from both parents. Twenty years ago, before a pharmacological treatment was developed, the life expectancy for children born with HT-1 was often only a few years. Today, with early detection and diagnosis, a protein-restricted diet and treatment, people with HT-1 are reaching adulthood and starting their own families. About us At a glance Rare diseases Therapeutic areas Haematology Immunology Specialty Care portfolio Investors Reports & presentations Share information Calendar Career Open positions Meet our employees Media Press releases Gallery Sobiplay Sitemap Cookie Policy Privacy Policy Terms of use Cookies Settings © Swedish Orphan Biovitrum AB (publ) Reg. no. 556038-9321

Sitemap About At a glance Focus on rare diseases Business strategy Partnership Board of directors Executive committee Corporate Governance Annual General Meetings Nomination Committee Committees Remuneration Auditors Articles of association History Therapeutic areas Haematology Immunology Specialty Care portfolio Research & development Investigator sponsored studies Managed Access Programmes Clinical studies and data privacy R&D pipeline Products Stories Sustainability Commitment to patients Patient centricity Humanitarian aid Responsible behaviour Code of Conduct Our Human Rights Statement Responsible sourcing Environmental footprint Transparency Disclosure of Payments to Healthcare Trade association membership Sustainability performance Investors Investment story Reports & presentations Other presentations Key financials Financial calendar Share information Alternative exchange monitor Historical share price look-up Ownership Share capital Analyst coverage Subscribe IR contacts Careers Our beliefs Our 'why' Our vision & values Our commitment Meet our employees Open positions Media Press releases News Media gallery Sobiplay Contacts Sitemap About us At a glance Rare diseases Therapeutic areas Haematology Immunology Specialty Care portfolio Investors Reports & presentations Share information Calendar Career Open positions Meet our employees Media Press releases Gallery Sobiplay Sitemap Cookie Policy Privacy Policy Terms of use Cookies Settings © Swedish Orphan Biovitrum AB (publ) Reg. no. 556038-9321